Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

568
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
568
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

311
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
311
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medium chain fatty acid sensing receptor GPR84 limits antitumor immunity mediated by CD4 T cells in mice.

ImmunoHorizons·2026
Same author

Orbital magnetoresistance in the antiferromagnet CoO driven by dynamic orbital angular momentum.

Science (New York, N.Y.)·2026
Same author

Predictive Modeling of Clonal Hematopoiesis Across Diverse Cohorts.

Blood advances·2026
Same author

Green Tea Consumption and Risk of All-Cause Mortality: Findings from a Prospective Cohort Study.

Nutrients·2026
Same author

Burden and Regional Disparities of MASH-Related Liver Cancer in the Asia-Pacific Region From 1990 to 2023.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

CD39 mRNA therapy attenuates localized acute inflammation: A novel anti-inflammatory strategy using cationic nanoliposomes.

Molecular therapy. Nucleic acids·2026

Related Experiment Video

Updated: Dec 13, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.4K

A Novel Method for Cancer Subtyping and Risk Prediction Using Consensus Factor Analysis.

Duc Tran1, Hung Nguyen1, Uyen Le2

  • 1Department of Computer Science and Engineering, University of Nevada, Reno, NV, United States.

Frontiers in Oncology
|July 28, 2020
PubMed
Summary
This summary is machine-generated.

A new method, Subtyping via Consensus Factor Analysis (SCFA), reliably identifies cancer subtypes and predicts patient risk scores by integrating multi-omics data. This approach improves accuracy and outperforms existing methods in cancer research.

Keywords:
cancer subtypingfactor analysismulti-omics integrationrisk score predictionsurvival analysis

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

559
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

1.9K

Related Experiment Videos

Last Updated: Dec 13, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.4K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

559
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

1.9K

Area of Science:

  • Oncology
  • Bioinformatics
  • Computational Biology

Background:

  • Cancer comprises diverse subtypes with varying clinical outcomes, posing a challenge for accurate differentiation.
  • Current multi-omics data integration methods for cancer subtyping face limitations in statistical assumptions and noise sensitivity.
  • Existing methods struggle to predict patient risk scores using comprehensive molecular data.

Purpose of the Study:

  • To introduce Subtyping via Consensus Factor Analysis (SCFA), a novel approach for robust cancer subtyping and risk score prediction.
  • To enhance the identification of molecular cancer subtypes with distinct clinical and survival profiles.
  • To develop a method that accurately predicts patient risk using integrated multi-omics data.

Main Methods:

  • Developed Subtyping via Consensus Factor Analysis (SCFA) to remove noise and identify consistent molecular patterns.
  • Applied SCFA to a large dataset of 7,973 samples across 30 cancer types from The Cancer Genome Atlas (TCGA).
  • Evaluated SCFA's performance against state-of-the-art methods for subtype discovery and risk prediction.

Main Results:

  • SCFA identified novel cancer subtypes with significantly different survival outcomes compared to existing approaches.
  • SCFA accurately predicted patient risk scores, showing high correlation with actual survival and vital status.
  • Integration of multiple data types improved both subtype discovery accuracy and risk prediction capabilities of SCFA.

Conclusions:

  • SCFA offers a powerful and reliable method for cancer subtyping and risk stratification using multi-omics data.
  • The performance of SCFA demonstrates the value of integrating diverse molecular data for a holistic understanding of cancer.
  • SCFA provides a significant advancement in precision oncology, with potential applications for personalized treatment strategies.